title: Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.
abstract: The nuclear export protein chromosome maintenance region 1, found to be elevated in non-Hodgkin's lymphomas, controls localization of critical tumor suppressor proteins. Nuclear localization of tumor suppressor proteins is necessary for their cell surveillance function. However, their nuclear exclusion by chromosome maintenance region 1 renders them ineffective making this nuclear transporter an attractive therapeutic target. We have identified selective inhibitors of nuclear export that lock tumor suppressor proteins in the cell nucleus leading to apoptosis of lymphoid but not normal cells. Our inhibitors induce tumor suppressor protein nuclear retention-dependent growth inhibition and apoptosis in a panel of non-Hodgkin's lymphoma cell lines. Western blot of nuclear protein fraction and confocal microscopy analysis demonstrated retention of major tumor suppressor proteins in the cell nucleus. Co-immunoprecipitation studies showed disruption of the tumor suppressor protein-chromosome maintenance region 1 interaction. Small inhibitor RNA knockdown of two major tumor suppressor proteins, p53 in wild-type protein-53 and protein 73 in mutant-protein-53, abrogated inhibitor activity. Oral administration of related inhibitor at 75 and 150 mg/kg resulted in 65 and 70% tumor reduction, respectively and subcutaneous injections of inhibitor (25 and 75 mg/kg) resulted in 70 and 74% suppression of non-Hodgkin's lymphoma tumor growth with no toxicity; residual tumors showed activation of the protein 73 pathway. Our study verifies chromosome maintenance region 1 as a therapeutic target in non-Hodgkin's lymphoma, indicating that this nuclear export protein warrants further clinical investigations.
authors: Department of Pathology, Wayne State University, Detroit MI, USA. azmia@karmanos.org
authors: Asfar S
authors: AS
authors: Azmi
authors: Ayad
authors: A
authors: Al-Katib
authors: Amro
authors: A
authors: Aboukameel
authors: Dilara
authors: D
authors: McCauley
authors: Michael
authors: M
authors: Kauffman
authors: Sharon
authors: S
authors: Shacham
authors: Ramzi M
authors: RM
authors: Mohammad
mesh_terms: D000179:Acrylates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D021581:Active Transport, Cell Nucleus / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D006801:Humans; D028884:Karyopherins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000378:metabolism*; D051379:Mice; D016513:Mice, SCID; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D016896:Treatment Outcome; D014230:Triazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays / Q000379:methods; D000097606:Exportin 1 Protein
chemical_list: D000179:Acrylates; D028884:Karyopherins; D018160:Receptors, Cytoplasmic and Nuclear; D014230:Triazoles; D000097606:Exportin 1 Protein; C576639:KPT-185
references: J Biol Chem. 2001 Jun 15;276(24):20805-8
references: 11303030
references: J Hematol Oncol. 2009 Feb 16;2:8
references: 19220884
references: Blood. 1993 Jun 1;81(11):3034-42
references: 8499639
references: Blood. 2012 Nov 29;120(23):4621-34
references: 23034282
references: Blood. 2011 Oct 6;118(14):3922-31
references: 21841164
references: Cell Death Differ. 2003 Apr;10(4):468-76
references: 12719724
references: Mol Cancer. 2009 Dec 03;8:115
references: 19958544
references: Oncotarget. 2011 May;2(5):378-92
references: 21623005
references: Biochem Pharmacol. 2012 Apr 15;83(8):1021-32
references: 22209898
references: Mol Cancer Ther. 2005 Jan;4(1):13-21
references: 15657349
references: Trends Cell Biol. 2007 Apr;17(4):193-201
references: 17317185
references: Trends Cell Biol. 2004 Oct;14(10):547-56
references: 15450977
references: Blood. 2012 Aug 30;120(9):1765-73
references: 22677130
references: Annu Rev Biochem. 2007;76:647-71
references: 17506639
references: Gastroenterology. 2013 Feb;144(2):447-456
references: 23089203
references: Cancer Res. 2006 Jan 1;66(1):212-20
references: 16397234
references: Oncogene. 2004 Aug 23;23(38):6524-34
references: 15322522
references: Nat Rev Cancer. 2004 Feb;4(2):106-17
references: 14732865
references: Clin Cancer Res. 1999 May;5(5):1085-91
references: 10353742
references: Clin Cancer Res. 2000 Dec;6(12):4950-6
references: 11156256
references: Curr Med Chem. 2008;15(26):2648-55
references: 18991627
references: Cancer Res. 2009 Jan 15;69(2):510-7
references: 19147564
references: Eur J Cancer. 2010 Apr;46(6):1122-31
references: 20156675
references: Curr Pharm Des. 2013;19(12):2318-25
references: 23082981
references: J Urol. 2013 Jun;189(6):2317-26
references: 23079374
references: Cancer Cell. 2003 Dec;4(6):463-76
references: 14706338
references: Br J Cancer. 1996 Aug;74(4):648-9
references: 8761384
references: Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9112-7
references: 10430904
references: Ann Oncol. 2012 Aug;23(8):2059-2064
references: 22241898
references: Lancet. 2012 Nov 24;380(9856):1797-9
references: 23079587
references: Oncogene. 2011 Jan 6;30(1):117-26
references: 20818437
references: Int Rev Cell Mol Biol. 2011;287:233-86
references: 21414590
references: Cell. 1997 Sep 19;90(6):1051-60
references: 9323133
references: Cell. 1997 Sep 19;90(6):1041-50
references: 9323132